AstraZeneca resolves Faslodex patent litigation in US
British drugmaker AstraZeneca Plc said it has entered into an agreement with Sandoz, the generic pharmaceuticals division of Novartis AG, to resolve Faslodex patent litigation in the U.S.
The company said it agreed to resolve the litigation relating to Sandoz's generic fulvestrant product, for which it is seeking FDA approval.
Fulvestrant is a type of hormonal therapy drug used to treat breast cancer.
The U.S. Faslodex patents are due to expire in January 2021, with paediatric exclusivity continuing until July 2021.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd